NASDAQ:ACGN Aceragen (ACGN) Stock Forecast, Price & News $0.38 0.00 (0.00%) (As of 09/1/2023) Add Compare Share Share Today's Range$0.38▼$0.3850-Day Range$0.38▼$1.5152-Week Range$0.36▼$16.00VolumeN/AAverage VolumeN/AMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Aceragen (NASDAQ:ACGN) StockAceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Read More ACGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACGN Stock News HeadlinesAugust 26, 2023 | ca.finance.yahoo.comACGN - Aceragen, Inc.August 8, 2023 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.16%September 24, 2023 | Stansberry Research (Ad)Experts: NVIDIA Now "Too Big to Succeed"Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.August 4, 2023 | finance.yahoo.comAceragen, Inc. to Delist from The Nasdaq Stock MarketJuly 12, 2023 | bizjournals.comCash-strapped public company in Durham moves to liquidate. Will shareholders get anything?July 11, 2023 | bizjournals.comInvestor wants its money back as Durham firm weighs bankruptcyJune 29, 2023 | chron.comAceragen: Q1 Earnings SnapshotMay 30, 2023 | finance.yahoo.comAceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingSeptember 24, 2023 | Stansberry Research (Ad)Experts: NVIDIA Now "Too Big to Succeed"Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.April 17, 2023 | bizjournals.comDurham public company begins furloughs as it searches for capitalMarch 30, 2023 | benzinga.comAceragen Stock (NASDAQ:ACGN), Guidance and ForecastMarch 5, 2023 | barrons.comAceragen Inc.March 1, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Aceragen (ACGN)February 6, 2023 | finance.yahoo.comAceragen Announces Recommendation of Data Monitoring Committee in Terra StudySee More Headlines Receive ACGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter. Email Address ACGN Company Calendar Last Earnings6/29/2023Today9/24/2023Next Earnings (Estimated)9/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACGN CUSIPN/A CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,360,000.00 Net MarginsN/A Pretax Margin-654.13% Return on Equity-215.27% Return on Assets-53.04% Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.32 Sales & Book Value Annual Sales$4.86 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.12Miscellaneous Outstanding Shares8,420,000Free Float6,196,000Market Cap$3.20 million OptionableNot Optionable Beta1.10 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. John C. Taylor (Age 52)Pres, CEO & Director Comp: $444.06kMs. Gwen ThomasAssociate Director of HR, Fin. & Admin.Ms. Christina AmendolaDirector of HRMr. Brian JackeySr. VP of Technical OperationsMs. Deepa NagpalGlobal Head of QualityDr. Shah Rahimian M.D.Ph.D., Medical Director & Global Clinical Lead for OncologyDr. Joanna Caroline Horobin Ch.B (Age 68)M.B., Advisor Mr. Louis J. Arcudi III (Age 62)M.B.A., MBA, Adviser More ExecutivesKey CompetitorsPalisade BioNASDAQ:PALISQZ BiotechnologiesNYSE:SQZScinai ImmunotherapeuticsNASDAQ:SCNIBrickell BiotechNASDAQ:BBIRubius TherapeuticsNASDAQ:RUBYView All CompetitorsInsidersMaxine GowenSold 51 sharesTotal: $26.01 ($0.51/share)Invest Corp PillarSold 3,605 sharesTotal: $5,695.90 ($1.58/share)Invest Corp PillarBought 26,965 shares on 5/17/2023Total: $38,290.30 ($1.42/share)View All Insider Transactions ACGN Stock - Frequently Asked Questions How have ACGN shares performed in 2023? Aceragen's stock was trading at $5.21 at the start of the year. Since then, ACGN stock has decreased by 92.7% and is now trading at $0.38. View the best growth stocks for 2023 here. When is Aceragen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023. View our ACGN earnings forecast. How were Aceragen's earnings last quarter? Aceragen, Inc. (NASDAQ:ACGN) released its earnings results on Thursday, June, 29th. The company reported ($2.94) earnings per share for the quarter. The business had revenue of $2.47 million for the quarter. What is Aceragen's stock symbol? Aceragen trades on the NASDAQ under the ticker symbol "ACGN." How do I buy shares of Aceragen? Shares of ACGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aceragen's stock price today? One share of ACGN stock can currently be purchased for approximately $0.38. How much money does Aceragen make? Aceragen (NASDAQ:ACGN) has a market capitalization of $3.20 million and generates $4.86 million in revenue each year. How can I contact Aceragen? Aceragen's mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for the company is www.iderapharma.com. The company can be reached via phone at (484) 348-1600, via email at ir@iderapharma.com, or via fax at 617-679-5592. This page (NASDAQ:ACGN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aceragen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.